Use of decentralized approach in a Phase 1 pharmacokinetic trial shows the ability to enable remote data collection and ...

Segal Trials, a privately held clinical research network specializing in acute schizophrenia and other psychiatric disorders, ...

Stuart Therapeutics completed a Phase 3 trial for ST-100, a treatment for dry eye disease, involving a randomized, ...

Previously, clinical research findings on cadonilimab in the treatment of various malignancies have been published in internationally renowned journals such as The Lancet, The Lancet Oncology, Nature ...

Collaboration to take Cytovation’s synthetic peptide, CY-101, into a Phase 2 trial for patients with adrenocortical carcinomaCancer Research UK’s Centre for Drug Development to run the trial at sites ...

Research has introduced daromun, therapeutic vaccines, and novel combinations for metastatic melanoma, reshaping the ...

Valneva’s vaccine was highly immunogenic in both dose groups. A full dose of the vaccine exhibited a more robust immune response compared to a half dose by providing protective antibody titers already ...

NDAQ:ZLAB) Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell ...

Cebranopadol is an investigational dual-nociceptin/orphanin FQ peptide receptor and µ-opioid peptide receptor agonist.

Biodexa Strengthens Management Team Appointment of Dr Gary A. Shangold as Chief Medical Officer Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (Nasdaq: BDRX), a clinical ...

The Phase II trial conducted by the Maria Skłodowska-Curie National Research Institute of Oncology (MSCNRIO) in Warsaw, the national reference centre for STS in Poland, has reached its enrolment ...